Nephria Bio is uniquely positioned to be the leader in the drive to develop a wearable dialysis solution. First, Nephria Bio’s parent company, EOFLOW, has already developed and released a wearable insulin pump to help manage type 1 diabetes. Our work is informed by a close partnership with EOFLOW and their technology. Additionally, Nephria Bio utilizes the unique compound “MXene’s,” to filter toxins from the body. Through its multidisciplinary partnerships throughout the field, Nephria Bio has been the first company to utilize these MXenes for dialysis. Our team of international, multidisciplinary experts have countless hours of combined experience in their respective fields. While developed by experts, Nephria Bio is first and foremost informed by the needs of patients. Over 750,000 people in the United States have end-stage kidney disease that requires dialysis. Nephria Bio has a patient advisory board that has been actively engaged in the process of our development. Our passion is providing these patients with the tools to live longer, healthier lives, all while utilizing a discreet, affordable, and wearable dialysis solution.